Relmada Therapeutics Balance Sheet - Annual (OTCMKTS:RLMD)

Add to My Stocks
$1.15 $0.2 (21.05%) RLMD stock closing price Sep 20, 2018 (Closing)

The fundamental analysis of this company requires a thorough look at Relmada Therapeutics balance sheet. Financial strength can be guaged by performing Relmada Therapeutics stock analysis and by analyzing the balance sheet. Annual results announcements include the release of all three financial statements, of which the balance sheet is one. Relmada Therapeutics had a long term debt of $- at the end of 2017. To understand the debt servicing capacity of the company, one needs to look at Relmada Therapeutics operating cash flow and Relmada Therapeutics revenue also. Relmada Therapeutics debt to equity ratio is .

View latest 10 year balance sheet data to check Relmada Therapeutics financial performance.
show more
Fiscal year is Jul - Jun2017201620152014
Cash1.71M8.5M22.46M25.56M
Marketable Securities----
Receivables----
Inventory----
Raw Materials----
Work In Progress----
Finished Goods----
Notes Receivable----
Other Current Assets--1.49M-
Total Current Assets
2.47M9.29M23.96M25.74M
Property Plant & Equipment----
Accumulated Depreciation----
Net Property Plant & Equipment
----
Investment & Advances----
Other Non-Current Assets----
Deferred Charges----
Intangibles----
Deposits & Other Assets----
Total Assets
2.83M10.24M24.39M25.76M
Notes Payable----
Accounts Payable-1.25M--
Current Portion Long-Term Debt----
Current Portion Capital Leases----
Accrued Expenses----
Income Taxes Payable----
Other Current Liabilities--14M25.58M
Total Current Liabilities
1.37M3.06M15.58M26.77M
Mortgages----
Deferred Taxes/Income----
Convertible Debt----
Long-Term Debt----
Non-Current Capital Leases----
Other Long-Term Liabilities----
Total Liabilities
1.37M3.2M15.58M26.87M
Minority Interest----
Preferred Stock----
Common Stock Net----
Capital Surplus86.83M86.12M84.92M54.16M
Retained Earnings-85.38M-79.09M-76.12M-55.31M
Treasury Stock----
Other Liabilities----
Shareholders Equity1.46M7.04M8.8M-1.1M
Total Liabilities & Shareholders Equity2.83M10.24M24.39M25.76M
All figures in USD. M: Millions of USD, B: Billions of USD.

Most investors just check the Relmada Therapeutics stock price, and Relmada Therapeutics historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Relmada Therapeutics PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like Relmada Therapeutics owns and has monetary significance. RLMD assets decreased from $10.24M in 2016 to $2.83M in 2017. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Relmada Therapeutics's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for RLMD stock stand at $1.37M.

Relmada Therapeutics Balance Sheet - Key Ratios